JP6587908B2 - Proton pump function promoter - Google Patents
Proton pump function promoter Download PDFInfo
- Publication number
- JP6587908B2 JP6587908B2 JP2015220123A JP2015220123A JP6587908B2 JP 6587908 B2 JP6587908 B2 JP 6587908B2 JP 2015220123 A JP2015220123 A JP 2015220123A JP 2015220123 A JP2015220123 A JP 2015220123A JP 6587908 B2 JP6587908 B2 JP 6587908B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- proton pump
- canna
- pump function
- hanacanna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010083204 Proton Pumps Proteins 0.000 title claims description 36
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 title claims 3
- 239000000203 mixture Substances 0.000 claims description 51
- 239000000284 extract Substances 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- 235000005273 Canna coccinea Nutrition 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000011734 sodium Substances 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 108010078791 Carrier Proteins Proteins 0.000 claims description 4
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical group [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 3
- 240000008555 Canna flaccida Species 0.000 claims 1
- 244000292211 Canna coccinea Species 0.000 description 32
- 102000006270 Proton Pumps Human genes 0.000 description 32
- 238000009472 formulation Methods 0.000 description 30
- 210000003491 skin Anatomy 0.000 description 29
- 238000004519 manufacturing process Methods 0.000 description 25
- 239000000047 product Substances 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 19
- 239000008213 purified water Substances 0.000 description 17
- 235000013305 food Nutrition 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 241000196324 Embryophyta Species 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- -1 hydrogen ions Chemical class 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 11
- 244000052616 bacterial pathogen Species 0.000 description 11
- 239000002537 cosmetic Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 241000233866 Fungi Species 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 230000002378 acidificating effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 239000006210 lotion Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000000469 ethanolic extract Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 108091006647 SLC9A1 Proteins 0.000 description 7
- 102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- 239000002304 perfume Substances 0.000 description 7
- 229940058015 1,3-butylene glycol Drugs 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 235000019437 butane-1,3-diol Nutrition 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 208000017520 skin disease Diseases 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- 229960000541 cetyl alcohol Drugs 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 206010021531 Impetigo Diseases 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 244000000010 microbial pathogen Species 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 238000010979 pH adjustment Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000234586 Cannaceae Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 229940073665 octyldodecyl myristate Drugs 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 241000684239 Canna x generalis Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000037862 Ion Transporter Human genes 0.000 description 1
- 108091006671 Ion Transporter Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940031957 lauric acid diethanolamide Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- IIGMITQLXAGZTL-UHFFFAOYSA-N octyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC IIGMITQLXAGZTL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 229940045845 sodium myristate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940045870 sodium palmitate Drugs 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 1
- JUQGWKYSEXPRGL-UHFFFAOYSA-M sodium;tetradecanoate Chemical compound [Na+].CCCCCCCCCCCCCC([O-])=O JUQGWKYSEXPRGL-UHFFFAOYSA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Non-Alcoholic Beverages (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
本発明は、カンナの抽出物を含有することを特徴とするプロトンポンプ機能促進剤、ならびに該プロトンポンプ機能促進剤を含む医薬品、医薬部外品、化粧品及び飲食品等の各種組成物に関するものである。 The present invention relates to a proton pump function promoter characterized by containing an extract of canna, and various compositions such as pharmaceuticals, quasi-drugs, cosmetics and foods and drinks containing the proton pump function promoter. is there.
健常な皮膚表面のｐＨは、通常４．５〜６．０の弱酸性を維持しており、このｐＨ環境は、病原性の細菌、ウィルス、真菌等の発育を阻止する役割を果たしている。何らかの原因により皮膚表面ｐＨのアルカリ化が起こると病原性の細菌、ウィルス、真菌等の増殖による皮膚疾患を発症するリスクが高くなる。例えば、アトピー性皮膚炎患者の皮膚表面ｐＨは、健常人よりも高く、主要な病原性細菌である黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）の検出率も高いことが報告されている（非特許文献１）。又、黄色ブドウ球菌は、伝染性膿痂疹、化膿性汗孔周囲炎やせつ等の皮膚疾患を引き起こすことが知られている（非特許文献２）。 The pH of a healthy skin surface usually maintains a weak acidity of 4.5 to 6.0, and this pH environment plays a role of preventing the growth of pathogenic bacteria, viruses, fungi and the like. If the skin surface pH is alkalized for some reason, the risk of developing skin diseases due to the growth of pathogenic bacteria, viruses, fungi and the like increases. For example, it has been reported that the skin surface pH of atopic dermatitis patients is higher than that of healthy individuals, and the detection rate of Staphylococcus aureus, which is a major pathogenic bacterium, is also high (Non-patent Document 1). . Staphylococcus aureus is known to cause skin diseases such as contagious impetigo, purulent periperitis, and depression (Non-patent Document 2).
そこで、皮膚を酸性に保つことによって、細菌類の発育を阻止する目的で用いられる酸性化粧水が開発されている（非特許文献３）。 Then, the acidic lotion used for the purpose of inhibiting the growth of bacteria by keeping the skin acidic has been developed (Non-patent Document 3).
しかしながら上述の化粧水の効果は、一時的であり、効果の持続性に問題があった。 However, the effect of the above-described lotion is temporary, and there is a problem with the sustainability of the effect.
又、上記のように黄色ブドウ球菌が皮膚疾患に関与することが明らかとなるにつれ、黄色ブドウ球菌に対して静菌もしくは殺菌作用を有する剤が開発されてきた。かかる剤としては、マンネンタケ子実体傘部抽出物（特許文献１）、クジン抽出物（特許文献２）、カバノアナタケ抽出物（特許文献３）、キトサン誘導体（特許文献４）等が開示されている。 In addition, as it has become clear that Staphylococcus aureus is involved in skin diseases as described above, agents having a bacteriostatic or bactericidal action against Staphylococcus aureus have been developed. As such an agent, Mannentake fruit body umbrella extract (Patent Document 1), Kujin extract (Patent Document 2), birch extract (Patent Document 3), chitosan derivative (Patent Document 4) and the like are disclosed.
しかしながら上記した剤は、ほとんどが黄色ブドウ球菌の静菌又は殺菌を図るもので、表皮ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ｅｐｉｄｅｒｍｉｄｉｓ）やミクロコッカス属菌（Ｍｉｃｒｏｃｏｃｃｕｓ ｓｐｅｃ）等の皮膚における常在菌にも静菌又は殺菌作用を及ぼしてしまうため、常在菌叢に変化をきたして、皮膚のホメオスタシスに影響を及ぼし、日和見感染を招く危険性を生じることもあった。 However, most of the agents mentioned above are for bacteriostasis or sterilization of Staphylococcus aureus, and are also bacteriostatic or sterilization against resident bacteria in the skin such as Staphylococcus epidermidis and Micrococcus species. It has an effect, which may change the resident flora, affect the homeostasis of the skin, and may cause an opportunistic infection.
皮膚表面ｐＨの弱酸性化には、汗や皮脂に含まれる成分の影響が考えられていたが、近年、表皮ケラチノサイトに存在するプロトンポンプが重要な役割を果たしており、プロトンポンプの一種であるナトリウム／水素イオン交換輸送体（Ｎａ＋／Ｈ＋ ｅｘｃｈａｎｇｅｒ：ＮＨＥ）の機能低下が皮膚表面ｐＨの上昇につながることが明らかにされている（非特許文献４、５）。プロトンポンプの機能低下にともなう皮膚表面ｐＨの上昇は、皮膚における病原性の細菌、ウィルス、真菌等の増殖につながる危険性がある。 The weak acidification of the skin surface pH was thought to be due to the effects of components contained in sweat and sebum, but in recent years the proton pump present in epidermal keratinocytes plays an important role, and is a type of proton pump, sodium. / Hydrogen ion transporter (Na + / H + exchanger: NHE) has been shown to lead to an increase in skin surface pH (Non-patent Documents 4 and 5). There is a risk that an increase in skin surface pH accompanying a decrease in the function of the proton pump may lead to the growth of pathogenic bacteria, viruses, fungi and the like in the skin.
プロトンポンプの機能を促進することにより、皮膚表面のｐＨを弱酸性に維持し、病原性の細菌、ウィルス、真菌等の発育を阻止することができる物質の開発が望まれる。 By promoting the function of the proton pump, it is desired to develop a substance that can maintain the pH of the skin surface to be weakly acidic and inhibit the growth of pathogenic bacteria, viruses, fungi and the like.
カンナは、カンナ（Ｃａｎｎａ）科カンナ（Ｃａｎｎａ）属に属する多年草で、地下に根茎（球根）をつくる。カンナには、多くの園芸品種があり、主に鑑賞用に用いられるが、これまで、抗炎症作用（特許文献５）、エストロゲン様作用（特許文献６）、ホルモン補充療法効果促進作用（特許文献７）、皮脂合成抑制作用（特許文献８）があることが知られている。しかしながら、プロトンポンプの機能促進効果については、これまで何ら知られていない。 Canna is a perennial that belongs to the genus Canna in the Canna family and makes a rhizome (bulb) underground. Kanna has many horticultural varieties and is mainly used for viewing. Until now, anti-inflammatory action (Patent Document 5), estrogen-like action (Patent Document 6), and hormone replacement therapy effect promoting action (Patent Document) 7) It is known that there is a sebum synthesis inhibiting action (Patent Document 8). However, nothing has been known about the function promoting effect of the proton pump.
本発明は、プロトンポンプの機能を促進することにより、皮膚表面のｐＨを弱酸性に維持することにより、病原性の細菌、ウィルス、真菌等の発育を阻止することができる、プロトンポンプ機能促進剤を提供することである。 The present invention relates to a proton pump function promoter capable of preventing the growth of pathogenic bacteria, viruses, fungi and the like by maintaining the pH of the skin surface weakly acidic by promoting the function of the proton pump. Is to provide.
本発明者らは、上記課題の解決に向け鋭意検討を行った結果、カンナの抽出物が優れたプロトンポンプ機能促進作用を有すること、それにより皮膚表面のｐＨを弱酸性に維持することにより、病原性の細菌、ウィルス、真菌等の発育を阻止することを見出し、本発明を完成するに至った。 As a result of intensive studies aimed at solving the above problems, the present inventors have found that the extract of canna has an excellent proton pump function promoting action, thereby maintaining the pH of the skin surface weakly acidic, The inventors have found that the growth of pathogenic bacteria, viruses, fungi and the like is inhibited, and have completed the present invention.
即ち、本発明は、以下の発明を包含する。
（１）カンナの抽出物を含有することを特徴とするプロトンポンプ機能促進剤。
（２）プロトンポンプがナトリウム／水素イオン交換輸送体である（１）記載の機能促進剤。
（３）（１）又は（２）記載の剤を含む、皮膚ｐＨ調整用外用組成物。
（４）皮膚外用組成物が医薬品又は医薬部外品である、（３）記載の皮膚外用組成物。
（５）皮膚外用組成物が化粧品である、（３）記載の皮膚外用組成物。
（６）（１）又は（２）記載の剤を含む、皮膚ｐＨ調整用飲食品。
（７）飲食品が健康食品、機能性食品、特定保健用食品、又は栄養補助食品である、（６）記載の飲食品。
That is, the present invention includes the following inventions.
(1) A proton pump function promoter characterized by containing an extract of canna.
(2) The function promoter according to (1), wherein the proton pump is a sodium / hydrogen ion exchange transporter.
(3) An external composition for skin pH adjustment, comprising the agent according to (1) or (2).
(4) The external composition for skin according to (3), wherein the external composition for skin is a pharmaceutical product or a quasi-drug.
(5) The external composition for skin according to (3), wherein the external composition for skin is a cosmetic.
(6) Food / beverage products for skin pH adjustment containing the agent of (1) or (2).
(7) The food or drink according to (6), wherein the food or drink is a health food, a functional food, a food for specified health use, or a dietary supplement.
本発明のカンナの抽出物は、プロトンポンプ機能促進効果に優れていた。この抽出物を含有することを特徴とするプロトンポンプ機能促進剤は、皮膚表面のｐＨを弱酸性に維持することにより、病原性の細菌、ウィルス、真菌等の発育を阻止する。又、本発明のプロトンポンプ機能促進剤は、作用が緩和な植物の抽出物を有効成分とすることから、副作用がなく安全性が高い。よって、医薬品、医薬部外品、化粧品、飲食品に安心して使用できる。 The canna extract of the present invention was excellent in the proton pump function promoting effect. The proton pump function promoter characterized by containing this extract inhibits the growth of pathogenic bacteria, viruses, fungi, and the like by maintaining the pH of the skin surface in a slightly acidic state. Further, the proton pump function promoter of the present invention uses a plant extract with a mild action as an active ingredient, and thus has no side effects and is highly safe. Therefore, it can be safely used for pharmaceuticals, quasi-drugs, cosmetics, and foods and drinks.
本発明でいうカンナには、ハナカンナ（Ｃａｎｎａ ｇｅｎｅｒａｌｉｓ Ｂａｉｌｅｙ）、ダンドク（Ｃａｎｎａ ｉｎｄｉｃａ Ｌ． ｖａｒ． ｏｒｉｅｎｔａｌｉｓ Ｈｏｏｋ． ｆｉｌ．）及びその種間雑種あるいは属間雑種等カンナ科に含まれる植物が挙げられ、ハナカンナやその種間雑種等は市販されている品種を、そして、ダンドクは九州等に自生するものを利用することができる。 Examples of the canna as used in the present invention include Hana canna (Canna generalis Bailey), Dangdoku (Canna indica L. var. Orientalis Hook. Fil.), And plants included in the Canna family such as interspecific hybrids or intergeneric hybrids. The hybrids that are available on the market can be used for cultivars and hybrids that are commercially available, and those that grow naturally in Kyushu etc. can be used.
本発明に用いるカンナの抽出物とは、植物体の葉、茎、花、実、根茎等の植物体の一部又は全草から抽出したものである。好ましくは、植物体の根茎から抽出して得られるものが良い。又、抽出には、これらの植物体をそのまま使用してもよく、乾燥、粉砕、細切等の処理を行ってもよい。 The extract of canna used in the present invention is extracted from a part of the plant body such as leaves, stems, flowers, fruits, rhizomes, or the whole plant. Preferably, those obtained by extraction from the rhizome of the plant body are good. In addition, these plants may be used as they are for extraction, or may be subjected to treatments such as drying, pulverization and shredding.
本発明のカンナの抽出方法は、特に限定されず、例えば、加熱抽出したものであっても良いし、常温又は低温で抽出したものであっても良い。抽出する溶媒としては、例えば、水、低級アルコール類（メタノール、エタノール、１−プロパノール、２−プロパノール、１−ブタノール、２−ブタノール等）、液状多価アルコール（１，３−ブチレングリコール、プロピレングリコール、グリセリン等）、ケトン類（アセトン、メチルエチルケトン等）、アセトニトリル、エステル類（酢酸エチル、酢酸ブチル等）、炭化水素類（ヘキサン、ヘプタン、流動パラフィン等）、エーテル類（エチルエーテル、テトラヒドロフラン、プロピルエーテル等）が挙げられる。好ましくは、水、低級アルコール及び液状多価アルコール等の極性溶媒が良く、特に好ましくは、水、エタノール、１，３−ブチレングリコール及びプロピレングリコールが良い。これらの溶媒は、１種でも２種以上を混合して用いても良い。 The extraction method of the canna of this invention is not specifically limited, For example, what was extracted by heating may be used, and what was extracted at normal temperature or low temperature may be used. Examples of the solvent to be extracted include water, lower alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.), liquid polyhydric alcohols (1,3-butylene glycol, propylene glycol). , Glycerin, etc.), ketones (acetone, methyl ethyl ketone, etc.), acetonitrile, esters (ethyl acetate, butyl acetate, etc.), hydrocarbons (hexane, heptane, liquid paraffin, etc.), ethers (ethyl ether, tetrahydrofuran, propyl ether) Etc.). Preferred are polar solvents such as water, lower alcohols and liquid polyhydric alcohols, and particularly preferred are water, ethanol, 1,3-butylene glycol and propylene glycol. These solvents may be used alone or in combination of two or more.
上記抽出物は抽出した溶液のまま用いても良く、必要に応じて濃縮、希釈、濾過、活性炭等による脱色、脱臭等の処理をして用いても良い。又、抽出した溶液を濃縮乾固、噴霧乾燥、凍結乾燥等の処理を行い、乾燥物として用いても良いし、カラム精製等を行い、有効成分を濃縮したり単離したりしてから用いても良い。本発明で用いるカンナは、天然由来の植物であり、カンナから抽出される成分は、多様な構造の化合物が多数同時に存在する混合物である。したがって、含有する成分の構造又は特性をすべて明らかにすることは困難であり、抽出物として扱うことが好ましい。 The above extract may be used as it is, or may be used after concentration, dilution, filtration, decolorization with activated carbon, deodorization, or the like, if necessary. In addition, the extracted solution may be processed by concentration, drying, spray drying, freeze drying, etc., and used as a dried product, or after column purification or the like, after concentrating or isolating active ingredients. Also good. The canna used in the present invention is a naturally derived plant, and the components extracted from the canna are a mixture in which a large number of compounds having various structures are present simultaneously. Therefore, it is difficult to clarify all the structures or characteristics of the contained components, and it is preferable to treat as an extract.
本発明でいうｐＨ調整とは、皮膚表面のｐＨを４．０〜６．５、好ましくは、４．５〜６．０の弱酸性に維持することをいう。 The pH adjustment in the present invention means maintaining the pH of the skin surface at a weak acidity of 4.0 to 6.5, preferably 4.5 to 6.0.
本発明でいうプロトンポンプとは、哺乳類細胞の膜に存在し、細胞内の水素イオン（Ｈ＋）を細胞外に能動輸送するタンパク質である。又、ナトリウム／水素イオン交換輸送体とは、細胞内の水素イオン（Ｈ＋）と細胞外のナトリウムイオン（Ｎａ＋）を１：１で交換輸送する交換輸送体タンパク質であり、細胞内のイオン濃度や浸透圧の調整に重要な役割を果たしている。 The proton pump referred to in the present invention is a protein that exists in the membrane of mammalian cells and actively transports intracellular hydrogen ions (H + ) to the outside of the cells. The sodium / hydrogen ion exchange transporter is an exchange transporter protein that exchanges and transports intracellular hydrogen ions (H + ) and extracellular sodium ions (Na + ) at a ratio of 1: 1. It plays an important role in adjusting the concentration and osmotic pressure.
本発明における「プロトンポンプ機能促進」とは、表皮ケラチノサイトにおけるプロトンポンプ遺伝子の発現及びそのタンパク質合成の促進をいうが、それに続く細胞内から細胞外へのＨ＋輸送の促進をも包含する。 “Proton pump function promotion” in the present invention refers to the expression of the proton pump gene in epidermal keratinocytes and the promotion of protein synthesis thereof, and also includes the subsequent promotion of H + transport from the inside of the cell to the outside of the cell.
表皮ケラチノサイトにおいて、プロトンポンプの一種であるＮＨＥが正常に機能すると細胞内にＮａ＋が取り込まれるとともに細胞外にＨ＋が輸送される。この細胞外に輸送されたＨ＋が皮膚表面ｐＨの弱酸性化に寄与する（Ｂｅｈｎｅ ＭＪ ｅｔ ａｌ，Ｊ．Ｂｉｏｌ．Ｃｈｅｍ．，２７７（４９），４７３９９−４７４０６（２００２），Ｃｈｏｉ ＥＨ ｅｔ ａｌ，Ｊ．Ｉｎｖｅｓｔ．Ｄｅｒｍａｔｏｌ．，１２７（６），２８４７−２８５６（２００７））。皮膚表面ｐＨが弱酸性であることは、病原性の細菌、ウィルス、真菌等の発育を阻止する役割を果たしており、皮膚表面ｐＨが上昇した皮膚では、主要な病原性細菌である黄色ブドウ球菌の検出率が高まり、この黄色ブドウ球菌がアトピー性皮膚炎、伝染性膿痂疹、化膿性汗孔周囲炎やせつ等の皮膚疾患に関連する（遠藤 薫ら，日本皮膚科学会誌，１１０（１），１９−２５（２０００），標準皮膚科学，第６版，池田重雄監修，医学書院，３６８−３７２（２００１））。したがって、本発明に用いるカンナの抽出物は、プロトンポンプ機能を促進する作用を介して、皮膚表面のｐＨを弱酸性に維持することにより、病原性の細菌、ウィルス、真菌等の発育を阻止することができる。又、カンナの抽出物は、当該病原性微生物の発育阻止作用を介して、病原性微生物に起因する皮膚疾患、例えば、アトピー性皮膚炎、伝染性膿痂疹、化膿性汗孔周囲炎やせつ等の予防や改善に有用である。 In epidermal keratinocytes, when NHE, which is a kind of proton pump, functions normally, Na + is taken into cells and H + is transported outside the cells. This extracellularly transported H + contributes to the weak acidification of the skin surface pH (Behne MJ et al, J. Biol. Chem., 277 (49), 47399-47406 (2002), Choi EH et al, J. Invest. Dermatol., 127 (6), 2847-2856 (2007)). The weakly acidic skin surface pH plays a role in preventing the growth of pathogenic bacteria, viruses, fungi, etc., and in the skin with an increased skin surface pH, the major pathogenic bacteria, Staphylococcus aureus Increasing the detection rate, this Staphylococcus aureus is associated with skin diseases such as atopic dermatitis, infectious impetigo, purulent periperitis, and depression (Satoshi Endo et al., Journal of the Japanese Dermatological Association, 110 (1) 19-25 (2000), Standard Dermatology, 6th edition, supervised by Shigeo Ikeda, Medical School, 368-372 (2001)). Therefore, the extract of canna used in the present invention prevents the growth of pathogenic bacteria, viruses, fungi and the like by maintaining the pH of the skin surface weakly acidic through the action of promoting the proton pump function. be able to. In addition, the extract of canna is used to prevent skin diseases caused by pathogenic microorganisms, for example, atopic dermatitis, infectious impetigo, purulent periantitis, and acne through the growth-inhibiting action of the pathogenic microorganism. It is useful for prevention and improvement.
本発明のプロトンポンプ機能促進剤を生体内に投与する場合は、そのまま投与することも可能であるが、本発明の効果を損なわない範囲で適当な添加物とともに皮膚外用組成物に含有して提供することが好ましい。本発明の皮膚外用組成物には、医薬品、医薬部外品、化粧品等が含まれる。 When the proton pump function promoter of the present invention is administered in vivo, it can be administered as it is, but it is provided in a composition for external use with an appropriate additive within a range not impairing the effects of the present invention. It is preferable to do. The external composition for skin of the present invention includes pharmaceuticals, quasi drugs, cosmetics and the like.
本発明のプロトンポンプ機能促進剤を医薬品に含有する場合は、薬理学的及び製剤学的に許容しうる添加物と混合し、患部に適用するのに適した製剤形態の各種製剤に製剤化することができる。薬理学的及び製剤学的に許容しうる添加物としては、その剤形、用途に応じて賦形剤、増粘剤、等張化剤、ｐＨ調節剤、安定化剤、防腐剤、保存剤、分散剤、乳化剤、ゲル化剤、色素、香料等を用いることができる。本発明の医薬品に適した形態は外用製剤であり、例えば、軟膏剤、クリーム剤、ゲル剤、液剤、貼付剤等が挙げられる。軟膏剤は、均質な半固形状の外用製剤をいい、油脂性軟膏、乳剤性軟膏、水溶性軟膏を含む。ゲル剤は、水不溶性成分の抱水化合物を水性液に懸濁した外用製剤をいう。液剤は、液状の外用製剤をいい、ローション剤、懸濁剤、乳剤、リニメント剤等を含む。 When the proton pump function promoter of the present invention is contained in a pharmaceutical product, it is mixed with pharmacologically and pharmaceutically acceptable additives and formulated into various preparations suitable for application to affected areas. be able to. Pharmacologically and pharmaceutically acceptable additives include excipients, thickeners, tonicity agents, pH regulators, stabilizers, preservatives, preservatives depending on the dosage form and application. , Dispersants, emulsifiers, gelling agents, pigments, fragrances and the like can be used. A form suitable for the pharmaceutical product of the present invention is an external preparation, and examples thereof include an ointment, a cream, a gel, a liquid, and a patch. The ointment refers to a homogeneous semi-solid external preparation, and includes an oily ointment, an emulsion ointment, and a water-soluble ointment. The gel is an external preparation in which a water-insoluble component hydrate compound is suspended in an aqueous liquid. The liquid preparation refers to a liquid external preparation and includes lotions, suspensions, emulsions, liniments and the like.
本発明のプロトンポンプ機能促進剤を医薬部外品や化粧品に含有する場合は、その剤形は、水溶液系、可溶化系、乳化系、粉末系、粉末分散系、油液系、ゲル系、軟膏系、エアゾール系、水−油二層系、又は水−油−粉末三層系等のいずれでもよい。又、当該医薬部外品や化粧品は、プロトンポンプ機能促進剤とともに、皮膚外用組成物において通常使用されている各種成分、添加剤、基剤等をその種類に応じて選択し、適宜配合し、当分野で公知の手法に従って製造することができる。その形態は、液状、乳液状、クリーム状、ゲル状、ペースト状、スプレー状等のいずれであってもよい。配合成分としては、例えば、油脂類（オリーブ油、ヤシ油、月見草油、ホホバ油、ヒマシ油、硬化ヒマシ油等）、ロウ類（ラノリン、ミツロウ、カルナウバロウ等）、炭化水素類（流動パラフィン、スクワレン、スクワラン、ワセリン等）、脂肪酸類（ラウリン酸、ミリスチン酸、パルミチン酸、ステアリン酸、ベヘニン酸等）、高級アルコール類（ミリスチルアルコール、セタノール、セトステアリルアルコール、ステアリルアルコール、ベヘニルアルコール等）、エステル類（ミリスチン酸イソプロピル、パルミチン酸イソプロピル、オクタン酸セチル、トリオクタン酸グリセリン、ミリスチン酸オクチルドデシル、ステアリン酸オクチル、ステアリン酸ステアリル等）、有機酸類（クエン酸、乳酸、α−ヒドロキシ酢酸、ピロリドンカルボン酸等）、糖類（マルチトール、ソルビトール、キシロビオース、Ｎ−アセチル−Ｄ−グルコサミン等）、蛋白質及び蛋白質の加水分解物、アミノ酸類及びその塩、ビタミン類、植物・動物抽出成分、種々の界面活性剤、保湿剤、紫外線吸収剤、抗酸化剤、安定化剤、防腐剤、殺菌剤、香料等が挙げられる。 When containing the proton pump function promoter of the present invention in a quasi drug or cosmetic, the dosage form is an aqueous solution system, a solubilization system, an emulsion system, a powder system, a powder dispersion system, an oil liquid system, a gel system, Any of an ointment system, an aerosol system, a water-oil two-layer system, or a water-oil-powder three-layer system may be used. In addition, the quasi-drug and cosmetics, together with the proton pump function promoter, select various components, additives, bases, etc. that are usually used in skin external compositions according to the type, and mix appropriately. It can be produced according to techniques known in the art. The form may be liquid, emulsion, cream, gel, paste, spray or the like. Examples of the ingredients include oils and fats (olive oil, palm oil, evening primrose oil, jojoba oil, castor oil, hydrogenated castor oil, etc.), waxes (lanolin, beeswax, carnauba wax, etc.), hydrocarbons (liquid paraffin, squalene, Squalane, petrolatum, etc.), fatty acids (lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, etc.), higher alcohols (myristyl alcohol, cetanol, cetostearyl alcohol, stearyl alcohol, behenyl alcohol, etc.), esters (myristin) Isopropyl acid, isopropyl palmitate, cetyl octanoate, glyceryl trioctanoate, octyldodecyl myristate, octyl stearate, stearyl stearate), organic acids (citric acid, lactic acid, α-hydroxyacetic acid, pyrrolidone Bonic acid, etc.), sugars (maltitol, sorbitol, xylobiose, N-acetyl-D-glucosamine, etc.), proteins and protein hydrolysates, amino acids and salts thereof, vitamins, plant / animal extract components, various interfaces Examples include activators, humectants, ultraviolet absorbers, antioxidants, stabilizers, preservatives, bactericides, and fragrances.
医薬部外品や化粧品の種類としては、例えば、化粧水、乳液、ジェル、美容液、一般クリーム、日焼け止めクリーム、パック、マスク、洗顔料、化粧石鹸、ファンデーション、おしろい、浴用剤、ボディローション、ボディシャンプー、ヘアシャンプー、ヘアコンディショナー、頭皮用ローション、頭皮用クリーム、ヘアトニック、育毛剤等が挙げられる。 The types of quasi-drugs and cosmetics include, for example, lotions, emulsions, gels, cosmetics, general creams, sun creams, packs, masks, facial cleansers, cosmetic soaps, foundations, funniers, bath preparations, body lotions, Examples include body shampoos, hair shampoos, hair conditioners, scalp lotions, scalp creams, hair tonics, and hair restorers.
本発明の皮膚外用組成物におけるプロトンポンプ機能促進剤の含有量は、表皮ケラチノサイトにおけるプロトンポンプ機能促進作用を発揮できる量である限り特に限定はされないが、例えばカンナの抽出物の乾燥固形物重量として０．００００１〜１０重量％が好ましく、０．０００１〜１重量％がより好ましい。上記の量はあくまで例示であって、組成物の種類や形態、一般的な使用量、効能・効果、及びコスト等を考慮して適宜設定・調整すればよい。 The content of the proton pump function promoter in the external composition for skin of the present invention is not particularly limited as long as it is an amount capable of exerting a proton pump function promoting action in epidermal keratinocytes. For example, as the dry solid weight of the extract of canna 0.00001-10 weight% is preferable and 0.0001-1 weight% is more preferable. The above amounts are merely examples, and may be appropriately set and adjusted in consideration of the type and form of the composition, the general usage amount, efficacy / effect, cost, and the like.
又、本発明のプロトンポンプ機能促進剤は、飲食品にも含有できる。本発明において、飲食品とは、健康食品、機能性食品、栄養補助食品、又は特定保健用食品を含む意味で用いられる。飲食品の形態は、食用に適した形態、例えば、固形状、液状、顆粒状、粒状、粉末状、カプセル状、クリーム状、ペースト状のいずれであってもよい。 Moreover, the proton pump function promoter of this invention can be contained also in food-drinks. In the present invention, the food or drink is used in the sense of including health food, functional food, nutritional supplement, or food for specified health use. The form of the food or drink may be any form suitable for edible use, for example, solid, liquid, granular, granular, powder, capsule, cream, or paste.
飲食品の種類としては、パン類、麺類、菓子類、乳製品、水産・畜産加工食品、油脂及び油脂加工食品、調味料、各種飲料（清涼飲料、炭酸飲料、美容ドリンク、栄養飲料、果実飲料、乳飲料等）及び該飲料の濃縮原液及び調整用粉末等が挙げられるが、これらに限定はされない。 The types of food and drink include bread, noodles, confectionery, dairy products, processed fishery and livestock products, processed oils and fats, processed foods, seasonings, various beverages (soft drinks, carbonated drinks, beauty drinks, nutritional drinks, fruit drinks) , Milk beverages, etc.) and concentrated concentrates and powders for adjustment of the beverages, but are not limited thereto.
本発明の飲食品は、その種類に応じて通常使用される添加物を適宜含有してもよい。添加物としては、食品衛生上許容されうる添加物であればいずれも使用できるが、例えば、ブドウ糖、ショ糖、果糖、異性化液糖、アスパルテーム、ステビア等の甘味料；クエン酸、リンゴ酸、酒石酸等の酸味料；デキストリン、澱粉等の賦形剤；結合剤、希釈剤、香料、着色料、緩衝剤、増粘剤、ゲル化剤、安定剤、保存剤、乳化剤、分散剤、懸濁化剤、防腐剤等が挙げられる。 The food / beverage products of this invention may contain the additive normally used according to the kind suitably. As the additive, any food hygiene-acceptable additive can be used. For example, sweeteners such as glucose, sucrose, fructose, isomerized liquid sugar, aspartame, stevia; citric acid, malic acid, Acidic agents such as tartaric acid; excipients such as dextrin and starch; binders, diluents, fragrances, colorants, buffers, thickeners, gelling agents, stabilizers, preservatives, emulsifiers, dispersants, suspensions Examples of the agent include preservatives and preservatives.
本発明の飲食品におけるカンナの抽出物の含有量は、表皮ケラチノサイトにおけるプロトンポンプ機能促進作用を発揮できる量であればよいが、対象飲食品の一般的な摂取量、飲食品の形態、効能・効果、呈味性、嗜好性及びコスト等を考慮して適宜設定すればよい。 The content of the extract of canna in the food or drink of the present invention may be an amount that can exert a proton pump function promoting action in epidermal keratinocytes, but the general intake of the target food or drink, the form of the food or drink, What is necessary is just to set suitably in consideration of an effect, taste, palatability, cost, etc.
次に、本発明を詳細に説明するため、具体的な実施例を挙げて説明する。これらの実施例は効果を具体的に説明するもので、発明の範囲を限定するものではない。実施例中の含有量は重量％である。 Next, in order to describe the present invention in detail, specific examples will be given and described. These examples specifically illustrate the effect and do not limit the scope of the invention. Content in an Example is weight%.
［実施例１］
カンナの抽出物を以下のとおり製造した。
（製造例１）ハナカンナ根茎の熱水抽出物の調製
ハナカンナ（根茎の乾燥品）１００ｇに精製水を２Ｌ加え、９０〜１００℃で２時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してハナカンナ根茎の熱水抽出物１．５ｇを得た。
[Example 1]
Canna extract was prepared as follows.
(Production Example 1) Preparation of Hanacanna rhizome hot water extract 2 L of purified water was added to 100 g of Hanacanna (dried rhizome), extracted at 90-100 ° C. for 2 hours, filtered, and the filtrate was concentrated and frozen. Drying gave 1.5 g of hot water extract of Hana canna rhizome.
（製造例２）ハナカンナ根茎の５０％エタノール抽出物の調製
ハナカンナ（根茎の乾燥品）１００ｇに５０％エタノール水溶液を２Ｌ加え、室温で１週間抽出した後、濾過し、その濾液を減圧濃縮し、凍結乾燥してハナカンナ根茎の５０％エタノール抽出物１．３ｇを得た。
(Production Example 2) Preparation of 50% ethanol extract of Hanacanna rhizome 2L of 50% ethanol aqueous solution was added to 100 g of Hanacanna (dried rhizome), extracted at room temperature for 1 week, filtered, and the filtrate was concentrated under reduced pressure. Lyophilization gave 1.3 g of a 50% ethanol extract of Hana canna rhizomes.
（製造例３）ハナカンナ根茎のエタノール抽出物の調製
ハナカンナ（根茎の乾燥品）１００ｇにエタノールを２Ｌ加え、室温で１週間抽出した後、濾過し、その濾液を減圧濃縮し、凍結乾燥してハナカンナ根茎のエタノール抽出物０．９ｇを得た。
(Production Example 3) Preparation of ethanol extract of Hana canna rhizome Add 2 L of ethanol to 100 g of Hana canna (dried rhizome), extract at room temperature for 1 week, filter, concentrate the filtrate under reduced pressure, freeze-dry and Hana canna 0.9 g of rhizome ethanol extract was obtained.
（製造例４）ハナカンナ全草の熱水抽出物の調製
ハナカンナ（全草の乾燥品）１００ｇに精製水を２Ｌ加え、９０〜１００℃で２時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してハナカンナ全草の熱水抽出物１．７ｇを得た。
(Manufacture example 4) Preparation of hot water extract of Hana canna whole plant 2 L of purified water was added to 100 g of Hana canna (dried whole plant), extracted at 90-100 ° C for 2 hours, filtered, and the filtrate was concentrated. Then, it was freeze-dried to obtain 1.7 g of a hot water extract of whole Hana canna.
（製造例５）ハナカンナ全草の５０％エタノール抽出物の調製
ハナカンナ（全草の乾燥品）１００ｇに５０％エタノール水溶液を２Ｌ加え、室温で１週間抽出した後、濾過し、その濾液を減圧濃縮し、凍結乾燥してハナカンナ全草の５０％エタノール抽出物１．２ｇを得た。
(Production Example 5) Preparation of 50% ethanol extract of Hana canna whole plant 2 L of 50% ethanol aqueous solution was added to 100 g of Hana canna (whole plant dried product), extracted for 1 week at room temperature, filtered, and the filtrate was concentrated under reduced pressure. And freeze-dried to obtain 1.2 g of a 50% ethanol extract of the whole Hana canna.
（製造例６）ハナカンナ全草のエタノール抽出物の調製
ハナカンナ（全草の乾燥品）１００ｇにエタノールを２Ｌ加え、室温で１週間抽出した後、濾過し、その濾液を減圧濃縮し、凍結乾燥してハナカンナ全草のエタノール抽出物０．７ｇを得た。
(Production Example 6) Preparation of ethanol extract of Hana canna whole plant 2 L of ethanol was added to 100 g of Hana canna (dried whole plant), extracted for 1 week at room temperature, filtered, and the filtrate was concentrated under reduced pressure and lyophilized. As a result, 0.7 g of an ethanol extract of whole hannacanna was obtained.
［実施例２］
ハナカンナの抽出物の効果の評価実験を次のとおり行った。
（試験例１）ケラチノサイトにおけるプロトンポンプ機能促進効果の評価
実施例１で製造したハナカンナの抽出物（製造例１〜６）のプロトンポンプ機能に及ぼす影響を、ＮＨＥ１のｍＲＮＡ発現量を指標に評価した。具体的方法について以下に記載する。
[Example 2]
The evaluation experiment of the effect of the extract of Hanacanna was performed as follows.
(Test Example 1) Evaluation of proton pump function promoting effect in keratinocytes The effect of Hanacanna extract (Production Examples 1 to 6) produced in Example 1 on the proton pump function was evaluated using the mRNA expression level of NHE1 as an index. . The specific method is described below.
ケラチノサイト由来ＨａＣａＴ細胞を６ｗｅｌｌプレートに１ｗｅｌｌあたり５×１０４個播種し、１０％ＦＢＳを含むＤＭＥＭ培養液にて、３７℃、５％ＣＯ２条件下で４日間培養した。次に、各試料（最終濃度１、１０μｇ／ｍＬ）を添加したＤＭＥＭ培養液にて、２４時間培養した後、総ＲＮＡの抽出を行った。細胞からの総ＲＮＡの抽出はＴＲＩＺＯＬ Ｒｅａｇｅｎｔ（Ｉｎｖｉｔｒｏｇｅｎ）を用いて行い、総ＲＮＡ量は分光光度計（ＮａｎｏＤｒｏｐ）を用いて２６０ｎｍにおける吸光度により求めた。ｍＲＮＡ発現量の測定は、細胞から抽出した総ＲＮＡを基にしてリアルタイムＲＴ−ＰＣＲ法により行った。リアルタイムＲＴ−ＰＣＲ法には、ＳｕｐｅｒＳｃｒｉｐｔＩＩＩ Ｐｌａｔｉｎｕｍ Ｔｗｏ−Ｓｔｅｐ ｑＲＴ−ＰＣＲ Ｋｉｔ ｗｉｔｈ ＳＹＢＲ Ｇｒｅｅｎ（Ｉｎｖｉｔｒｏｇｅｎ）を用いた。すなわち、５００ｎｇの総ＲＮＡを逆転写反応後、ＰＣＲ反応（９５℃：１５秒間、６０℃：３０秒間、４０ｃｙｃｌｅｓ）を行った。その他の操作は定められた方法に従い、ＮＨＥ１ ｍＲＮＡの発現量を、内部標準であるβ−アクチン ｍＲＮＡの発現量に対する割合として求めた。ＮＨＥ１発現量は、コントロールのＮＨＥ１ ｍＲＮＡの発現量に対する試料添加群のＮＨＥ１ ｍＲＮＡの発現量の比率として算出した。尚、ＮＨＥ１及びβ−アクチン用のプライマーは、以下に示したものを使用した。 Keratinocyte-derived HaCaT cells were seeded on a 6-well plate at 5 × 10 4 cells per well, and cultured in a DMEM culture solution containing 10% FBS under conditions of 37 ° C. and 5% CO 2 for 4 days. Next, after culturing for 24 hours in a DMEM culture solution to which each sample (final concentration 1, 10 μg / mL) was added, total RNA was extracted. Extraction of total RNA from the cells was performed using TRIZOL Reagent (Invitrogen), and the total RNA amount was determined by absorbance at 260 nm using a spectrophotometer (NanoDrop). Measurement of mRNA expression level was performed by real-time RT-PCR method based on total RNA extracted from cells. For the real-time RT-PCR method, SuperScriptIII Platinum Two-Step qRT-PCR Kit with SYBR Green (Invitrogen) was used. Specifically, 500 ng of total RNA was subjected to a reverse transcription reaction, followed by a PCR reaction (95 ° C .: 15 seconds, 60 ° C .: 30 seconds, 40 cycles). For other operations, the expression level of NHE1 mRNA was determined as a ratio to the expression level of β-actin mRNA, which is an internal standard, in accordance with a predetermined method. The NHE1 expression level was calculated as the ratio of the NHE1 mRNA expression level of the sample addition group to the control NHE1 mRNA expression level. In addition, the primer shown below was used for the primer for NHE1 and (beta) -actin.
ＮＨＥ１用のプライマーセット
ＧＣＣＣＴＧＴＴＡＡＴＣＡＴＴＣＣＧＴＣ（配列番号１）
ＣＡＣＡＴＧＧＡＡＡＣＣＴＡＴＣＴＴＣＡＴＧＡＧ（配列番号２）
β−アクチン用のプライマーセット
ＣＡＣＴＣＴＴＣＣＡＧＣＣＴＴＣＣＴＴＣＣ（配列番号３）
ＧＴＧＴＴＧＧＣＧＴＡＣＡＧＧＴＣＴＴＴＧ（配列番号４）
Primer set GCCCTGTTAATCATTCCGTC for NHE1 (SEQ ID NO: 1)
CACATGGGAAACCCTATTCTCATGAG (SEQ ID NO: 2)
Primer set CACTCTCCCAGCCTCTCTCCC for β-actin (SEQ ID NO: 3)
GTGTTGCGCGTACAGGTCTTTG (SEQ ID NO: 4)
これらの試験結果を表１に示した。その結果、ハナカンナの抽出物（製造例１〜６）の全てに、比較品のダイズの抽出物を上回る顕著なプロトンポンプ機能促進効果が認められた。又、プロトンポンプ機能促進効果は、全草よりも根茎の抽出物の方が、エタノールよりも熱水抽出物の方が高かった。 The test results are shown in Table 1. As a result, all the Hanacanna extracts (Production Examples 1 to 6) exhibited a remarkable proton pump function promoting effect over the comparative soybean extract. In addition, the effect of promoting the proton pump function was higher in the rhizome extract than in the whole plant, and in the hot water extract than in ethanol.
［実施例３］製品の処方例
製造例１〜６で製造したハナカンナの抽出物を含有した製品の処方例を以下に示す。
[Example 3] Formulation example of product The formulation example of the product containing the extract of Hanacanna manufactured in Production Examples 1 to 6 is shown below.
（処方例１）ローション
処方 含有量(重量％）
１．ハナカンナの抽出物 ０．１
２．１，３−ブチレングリコール ８．０
３．グリセリン ２．０
４．キサンタンガム ０．０２
５．クエン酸 ０．０１
６．クエン酸ナトリウム ０．１
７．エタノール ５．０
８．パラオキシ安息香酸メチル ０．１
９．ポリオキシエチレン硬化ヒマシ油（４０Ｅ．Ｏ．） ０．１
１０．香料 ０．１
１１．精製水 残量
［製造方法］成分１〜６及び１１と、成分７〜１０をそれぞれ均一に溶解した後、両者を混合し濾過しローションを調製する。
(Formulation example 1) Lotion Formulation Content (wt%)
1. Hanacanna extract 0.1
2. 1,3-butylene glycol 8.0
3. Glycerin 2.0
4). Xanthan gum 0.02
5). Citric acid 0.01
6). Sodium citrate 0.1
7). Ethanol 5.0
8). Methyl paraoxybenzoate 0.1
9. Polyoxyethylene hydrogenated castor oil (40E.O.) 0.1
10. Fragrance 0.1
11. Purified water Residual amount [Production method] Components 1 to 6 and 11 and components 7 to 10 are uniformly dissolved, and then mixed and filtered to prepare a lotion.
（処方例２） クリーム
処方 含有量(重量％）
１．ハナカンナの抽出物 ０．１
２．スクワラン ５．５
３．オリーブ油 ３．０
４．ステアリン酸 ２．０
５．ミツロウ ２．０
６．ミリスチン酸オクチルドデシル ３．５
７．ポリオキシエチレンセチルエーテル（２０Ｅ．Ｏ．） ３．０
８．ベヘニルアルコール １．５
９．モノステアリン酸グリセリン ２．５
１０．香料 ０．１
１１．パラオキシ安息香酸メチル ０．２
１２．パラオキシ安息香酸エチル ０．０５
１３．１，３−ブチレングリコール ８．５
１４．精製水 残量
［製造方法］成分２〜９を加熱溶解して混合し、７０℃に保ち油相とする。成分１及び１１〜1４を加熱溶解して混合し、７５℃に保ち水相とする。次いで、油相に水相を加えて乳化して、かき混ぜながら冷却し、４５℃で成分１０を加え、さらに３０℃まで冷却して製品とする。
(Formulation example 2) Cream Formulation Content (wt%)
1. Hanacanna extract 0.1
2. Squalane 5.5
3. Olive oil 3.0
4). Stearic acid 2.0
5). Beeswax 2.0
6). Octyldodecyl myristate 3.5
7). Polyoxyethylene cetyl ether (20E.O.) 3.0
8). Behenyl alcohol 1.5
9. Glycerol monostearate2.5
10. Fragrance 0.1
11. Methyl paraoxybenzoate 0.2
12 Ethyl paraoxybenzoate 0.05
13.1,3-Butylene glycol 8.5
14 Purified water Remaining amount [Production method] Components 2 to 9 are dissolved by heating and mixed, and kept at 70 ° C. to obtain an oil phase. Ingredients 1 and 11 to 14 are heated and dissolved, mixed, and kept at 75 ° C. to form an aqueous phase. Next, the aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 10 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.
（処方例３）乳液
処方 含有量(重量％）
１．ハナカンナの抽出物 ０．１
２．スクワラン ５．０
３．オリーブ油 ５．０
４．ホホバ油 ５．０
５．セタノール １．５
６．モノステアリン酸グリセリン ２．０
７．ポリオキシエチレンセチルエーテル（２０Ｅ．Ｏ．） ３．０
８．ポリオキシエチレンソルビタンモノオレエート（２０Ｅ．Ｏ．） ２．０
９．香料 ０．１
１０．プロピレングリコール １．０
１１．グリセリン ２．０
１２．パラオキシ安息香酸メチル ０．２
１３．精製水 残量
［製造方法］成分２〜８を加熱溶解して混合し、７０℃に保ち油相とする。成分１及び１０〜１３を加熱溶解して混合し、７５℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、４５℃で成分９を加え、さらに３０℃まで冷却して製品とする。
(Formulation Example 3) Emulsion Formulation Content (wt%)
1. Hanacanna extract 0.1
2. Squalane 5.0
3. Olive oil 5.0
4). Jojoba oil 5.0
5). Cetanol 1.5
6). Glycerol monostearate 2.0
7). Polyoxyethylene cetyl ether (20E.O.) 3.0
8). Polyoxyethylene sorbitan monooleate (20E.O.) 2.0
9. Fragrance 0.1
10. Propylene glycol 1.0
11. Glycerin 2.0
12 Methyl paraoxybenzoate 0.2
13. Purified water Remaining [Manufacturing method] Components 2 to 8 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 10-13 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 9 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.
（処方例４）ゲル剤
処方 含有量(重量％）
１．ハナカンナの抽出物 ０．１
２．エタノール ５．０
３．パラオキシ安息香酸メチル ０．１
４．ポリオキシエチレン硬化ヒマシ油（６０Ｅ．О．） ０．１
５．香料 適量
６．１，３−ブチレングリコール ５．０
７．グリセリン ５．０
８．キサンタンガム ０．１
９．カルボキシビニルポリマー ０．２
１０．水酸化カリウム ０．２
１１．精製水 残量
［製造方法］成分２〜５と、成分１及び６〜１１をそれぞれ均一に溶解し、両者を混合して製品とする。
(Formulation example 4) Gel formulation Formulation content (% by weight)
1. Hanacanna extract 0.1
2. Ethanol 5.0
3. Methyl paraoxybenzoate 0.1
4). Polyoxyethylene hydrogenated castor oil (60E.O.) 0.1
5). Perfume appropriate amount 6.1,3-butylene glycol 5.0
7). Glycerin 5.0
8). Xanthan gum 0.1
9. Carboxyvinyl polymer 0.2
10. Potassium hydroxide 0.2
11. Purified water Residual amount [Production method] Components 2 to 5 and components 1 and 6 to 11 are uniformly dissolved and mixed to obtain a product.
（処方例５）軟膏
処方 含有量(重量％）
１．ハナカンナの抽出物 ２．０
２．ポリオキシエチレンセチルエーテル（３０Ｅ．Ｏ．） ２．０
３．モノステアリン酸グリセリン １０．０
４．流動パラフィン ５．０
５．セタノール ６．０
６．パラオキシ安息香酸メチル ０．１
７．プロピレングリコール １０．０
８．精製水 残量
［製造方法］成分２〜５を加熱溶解して混合し、７０℃に保ち油相とする。成分１及び６〜８を加熱溶解して混合し、７５℃に保ち水相とする。油相に水相を加えて乳化し、かき混ぜながら３０℃まで冷却して製品とする。
(Formulation Example 5) Ointment Formulation Content (% by weight)
1. Hanacanna Extract 2.0
2. Polyoxyethylene cetyl ether (30E.O.) 2.0
3. Glycerol monostearate 10.0
4). Liquid paraffin 5.0
5). Cetanol 6.0
6). Methyl paraoxybenzoate 0.1
7). Propylene glycol 10.0
8). Purified water Remaining [Manufacturing method] Components 2 to 5 are dissolved by heating and mixed, and kept at 70 ° C. to obtain an oil phase. Ingredients 1 and 6 to 8 are dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the product is cooled to 30 ° C. with stirring to obtain a product.
（処方例６）パック
処方 含有量(重量％）
１．ハナカンナの抽出物 ０．１
２．ポリビニルアルコール １２．０
３．エタノール ５．０
４．１，３−ブチレングリコール ８．０
５．パラオキシ安息香酸メチル ０．２
６．ポリオキシエチレン硬化ヒマシ油（２０Ｅ．Ｏ．） ０．５
７．クエン酸 ０．１
８．クエン酸ナトリウム ０．３
９．香料 適量
１０．精製水 残量
［製造方法］成分１〜１０を均一に溶解し製品とする。
(Formulation Example 6) Pack Formulation Content (wt%)
1. Hanacanna extract 0.1
2. Polyvinyl alcohol 12.0
3. Ethanol 5.0
4.1,3-Butylene glycol 8.0
5). Methyl paraoxybenzoate 0.2
6). Polyoxyethylene hydrogenated castor oil (20 EO) 0.5
7). Citric acid 0.1
8). Sodium citrate 0.3
9. Perfume appropriate amount10. Purified water Remaining amount [Production method] Components 1 to 10 are uniformly dissolved to obtain a product.
（処方例７）ファンデーション
処方 含有量(重量％）
１．ハナカンナの抽出物 １．０
２．ステアリン酸 ２．４
３．ポリオキシエチレンソルビタンモノステアレート（２０Ｅ．Ｏ．） １．０
４．ポリオキシエチレンセチルエーテル（２０Ｅ．Ｏ．） ２．０
５．セタノール １．０
６．液状ラノリン ２．０
７．流動パラフィン ３．０
８．ミリスチン酸イソプロピル ６．５
９．パラオキシ安息香酸ブチル ０．１
１０．カルボキシメチルセルロースナトリウム ０．１
１１．ベントナイト ０．５
１２．プロピレングリコール ４．０
１３．トリエタノールアミン １．１
１４．パラオキシ安息香酸メチル ０．２
１５．二酸化チタン ８．０
１６．タルク ４．０
１７．ベンガラ １．０
１８．黄酸化鉄 ２．０
１９．香料 適量
２０．精製水 残量
［製造方法］成分２〜９を加熱溶解し、８０℃に保ち油相とする。成分２０に成分１０をよく膨潤させ、続いて、成分１及び１１〜１４を加えて均一に混合する。これに粉砕機で粉砕混合した成分１５〜１８を加え、水相とする。水相を８０℃に昇温し、油相に水相を徐々に加え乳化する。その後、撹拌しながら冷却し、４５℃で成分１９を加え、３０℃まで冷却して製品とする。
(Formulation Example 7) Foundation Formulation Content (wt%)
1. Hanacanna extract 1.0
2. Stearic acid 2.4
3. Polyoxyethylene sorbitan monostearate (20E.O.) 1.0
4). Polyoxyethylene cetyl ether (20E.O.) 2.0
5). Cetanol 1.0
6). Liquid lanolin 2.0
7). Liquid paraffin 3.0
8). Isopropyl myristate 6.5
9. Butyl paraoxybenzoate 0.1
10. Sodium carboxymethylcellulose 0.1
11. Bentonite 0.5
12 Propylene glycol 4.0
13. Triethanolamine 1.1
14 Methyl paraoxybenzoate 0.2
15. Titanium dioxide 8.0
16. Talc 4.0
17. Bengala 1.0
18. Yellow iron oxide 2.0
19. Perfume proper amount20. Purified water Residual amount [Production method] Components 2 to 9 are dissolved by heating and kept at 80 ° C. to form an oil phase. Swell component 10 well with component 20, then add components 1 and 11-14 and mix uniformly. To this, ingredients 15 to 18 pulverized and mixed with a pulverizer are added to obtain an aqueous phase. The aqueous phase is heated to 80 ° C., and the aqueous phase is gradually added to the oil phase to emulsify. Then, it cools with stirring, and the component 19 is added at 45 degreeC, and it cools to 30 degreeC to make a product.
（処方例８）固形石鹸
処方 含有量(重量％）
１．ハナカンナの抽出物 ０．１
２．石鹸素地（＊） ８０．０
３．グリセリン １０．０
４．ソルビトール １．０
５．エデト酸 ０．１
６．酸化チタン ０．１
７．香料 適量
８．精製水 残量
（＊）ラウリン酸ナトリウム、ミリスチン酸ナトリウム、パルミチン酸ナトリウム、ステアリン酸ナトリウム、オレイン酸ナトリウムを含む高級脂肪酸ナトリウム混合物
［製造方法］全成分を混合して、ミキサー及びローラーで混練し、プロッダーで圧縮することによって棒状の成型物に型打ちし、次いで、成形物を冷却し、乾燥することによって、製品を得る。
(Formulation example 8) Solid soap Formulation Content (% by weight)
1. Hanacanna extract 0.1
2. Soap base (*) 80.0
3. Glycerin 10.0
4). Sorbitol 1.0
5). Edetic acid 0.1
6). Titanium oxide 0.1
7). Perfume appropriate amount 8. Purified water Remaining amount (*) High fatty acid sodium mixture containing sodium laurate, sodium myristate, sodium palmitate, sodium stearate, sodium oleate [Production method] Mix all ingredients, knead with mixer and roller, The product is obtained by stamping into a rod-shaped molding by compressing with a pudder and then cooling and drying the molding.
（処方例９）ボディ用洗浄料
処方 含有量(重量％）
１．ハナカンナの抽出物 ０．２
２．ステアリン酸 １０．０
３．パルミチン酸 ８．０
４．ミリスチン酸 １２．０
５．ラウリン酸 ４．０
６．オレイルアルコール １．５
７．精製ラノリン １．０
８．ヤシ油脂肪酸ジエタノールアミド １．０
９．グリセリン １０．０
１０．水酸化カリウム ６．０
１１．香料 適量
１２．防腐剤 適量
１３．金属イオン封鎖剤 適量
１４．精製水 残量
［製造方法］成分２〜５を加熱溶解して混合し、７０℃に保ち油相とする。成分１４の適量に成分１０を溶解し、油相に添加しケン化を行う。続いて、成分６〜９をケン化物に添加し、室温でさらに成分１、１１〜１３及び残りの成分１４を添加する。
(Formulation Example 9) Body cleanser Formulation Content (wt%)
1. Hanacanna extract 0.2
2. Stearic acid 10.0
3. Palmitic acid 8.0
4). Myristic acid 12.0
5. Lauric acid 4.0
6). Oleyl alcohol 1.5
7). Purified lanolin 1.0
8). Palm oil fatty acid diethanolamide 1.0
9. Glycerin 10.0
10. Potassium hydroxide 6.0
11. Perfume appropriate amount 12. Preservative appropriate amount13. Metal ion sequestering agent Purified water Remaining [Production method] Components 2 to 5 are dissolved by heating and mixed, and kept at 70 ° C. to obtain an oil phase. The component 10 is dissolved in an appropriate amount of the component 14 and added to the oil phase for saponification. Subsequently, components 6 to 9 are added to the saponified product, and components 1, 11 to 13 and the remaining component 14 are further added at room temperature.
（処方例１０）ヘアローション
処方 含有量(重量％）
１．ハナカンナの抽出物 ０．２
２．ステアリン酸 ５．０
３．セチルアルコール ５．０
４．流動パラフィン ２．０
５．グリセリンモノステアレート １．３
６．ソルビタンモノオレート １．５
７．ポリオキシエチレンソルビタンモノオレエート（１０Ｅ．Ｏ．） ０．８
８．グリセリン ６．０
９．防腐剤 適量
１０．精製水 残量
［製造方法］成分２〜７を加熱溶解して混合し、７０℃に保ち油相とする。成分１及び８〜１０を加熱溶解して混合し、７５℃に保ち水相とする。油相に水相を加えて乳化し、かき混ぜながら冷却して製品とする。
(Formulation example 10) Hair lotion Formulation Content (wt%)
1. Hanacanna extract 0.2
2. Stearic acid 5.0
3. Cetyl alcohol 5.0
4). Liquid paraffin 2.0
5. Glycerin monostearate 1.3
6). Sorbitan monooleate 1.5
7). Polyoxyethylene sorbitan monooleate (10E.O.) 0.8
8). Glycerin 6.0
9. Preservative appropriate amount10. Purified water Remaining amount [Production method] Components 2 to 7 are heated and dissolved and mixed, and kept at 70 ° C. to obtain an oil phase. Ingredients 1 and 8 to 10 are dissolved by heating and mixed, and kept at 75 ° C. to form an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring to obtain a product.
（処方例１１）ヘアトニック
処方 含有量(重量％）
１．ハナカンナの抽出物 ２．０
２．９５％エタノール ６０．０
３．グリセリン ２．０
４．精製水 残量
［製造方法］成分１を２に溶解し、成分３及び４を加え、十分撹拌混合し、製品とする。
(Prescription Example 11) Hair Tonic Formulation Content (wt%)
1. Hanacanna Extract 2.0
2.95% ethanol 60.0
3. Glycerin 2.0
4). Purified water remaining [Manufacturing method] Dissolve component 1 in 2, add components 3 and 4, and stir and mix thoroughly to obtain a product.
（処方例１２）シャンプー
処方 含有量(重量％）
１．ハナカンナの抽出物 ０．１
２．アルキル硫酸トリエタノールアミン １８．０
３．ラウリン酸ジエタノールアミド ３．０
４．メチルセルロース ０．５
５．香料 適量
６．精製水 残量
［製造方法］成分６に成分４を均一に溶解した後、成分１及び２を加え、７０〜７５℃で加熱溶解した後、成分３を加え、冷却途中に成分５を加え３０℃まで冷却し製品とする。
(Formulation example 12) Shampoo Formulation Content (wt%)
1. Hanacanna extract 0.1
2. Alkyl sulfate triethanolamine 18.0
3. Lauric acid diethanolamide 3.0
4). Methylcellulose 0.5
5. Perfume appropriate amount 6. Purified water remaining amount [Manufacturing method] After component 4 is uniformly dissolved in component 6, components 1 and 2 are added, heated and dissolved at 70 to 75 ° C., component 3 is added, and component 5 is added during cooling 30 Cool to ℃ to make the product.
（処方例１３）浴用剤
処方 含有量(重量％）
１．ハナカンナの抽出物 ５．０
２．炭酸水素ナトリウム ５０．０
３．黄色２０２号 適量
４．香料 適量
５．無水硫酸ナトリウム 残量
［製造方法］成分１〜５を均一に混合し製品とする。
(Formulation example 13) Bath agent Formulation Content (% by weight)
1. Hanacanna extract 5.0
2. Sodium bicarbonate 50.0
3. Yellow 202 No. 4 Perfume appropriate amount 5. Residual amount of anhydrous sodium sulfate [Production method] Components 1 to 5 are uniformly mixed to obtain a product.
（処方例１４）錠剤
処方 含有量(重量％）
１．ハナカンナの抽出物 １．０
２．乾燥コーンスターチ ２５．０
３．カルボキシメチルセルロースカルシウム ２４．０
４．微結晶セルロース ４０．０
５．ポリビニルピロリドン ７．０
６．タルク ３．０
［製造方法］成分１〜５を混合し、次いで１０％の水を結合剤として加えて、押出し造粒後乾燥する。成形した顆粒に成分６を加えて混合し打錠する。１錠０．５２ｇとする。
(Formulation Example 14) Tablet Formulation Content (% by weight)
1. Hanacanna extract 1.0
2. Dried corn starch 25.0
3. Carboxymethylcellulose calcium 24.0
4). Microcrystalline cellulose 40.0
5. Polyvinylpyrrolidone 7.0
6). Talc 3.0
[Production Method] Components 1 to 5 are mixed, and 10% water is added as a binder, followed by extrusion granulation and drying. Ingredient 6 is added to the molded granules, mixed and compressed into tablets. One tablet is 0.52 g.
（処方例１５）飲料
処方 含有量(重量％）
１．ハナカンナの抽出物 ０．１
２．ステビア ０．０５
３．リンゴ酸 ５．０
４．アスコルビン酸ナトリウム １．０
５．香料 ０．１
６．精製水 残量
［製造方法］成分１〜５を成分６の一部の精製水に撹拌溶解する。次いで、成分６の残りの精製水を加えて混合し、９０℃に加熱して５０ｍＬのガラス瓶に充填する。
(Prescription Example 15) Beverage Formulation Content (% by weight)
1. Hanacanna extract 0.1
2. Stevia 0.05
3. Malic acid 5.0
4). Sodium ascorbate 1.0
5. Fragrance 0.1
6). Purified water Remaining amount [Production method] Components 1 to 5 are stirred and dissolved in a part of purified water of component 6. The remaining purified water of Component 6 is then added and mixed, heated to 90 ° C. and filled into a 50 mL glass bottle.
本発明に関わる、カンナの抽出物を含有することを特徴とするプロトンポンプ機能促進剤は、皮膚表面のｐＨを弱酸性に維持することにより、病原性微生物の発育を阻止する。従って、病原性微生物に起因する皮膚疾患、例えば、アトピー性皮膚炎、伝染性膿痂疹、化膿性汗孔周囲炎やせつ等の予防や改善を目的とした医薬品、医薬部外品、化粧品、及び飲食品の製造分野において利用できる。 The proton pump function promoter according to the present invention, which contains an extract of canna, inhibits the growth of pathogenic microorganisms by maintaining the pH of the skin surface at a weak acidity. Therefore, pharmaceuticals, quasi-drugs, cosmetics for the purpose of prevention and improvement of skin diseases caused by pathogenic microorganisms, such as atopic dermatitis, contagious impetigo, purulent peritonitis and depression, And can be used in the field of food and beverage production.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015220123A JP6587908B2 (en) | 2015-11-10 | 2015-11-10 | Proton pump function promoter |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015220123A JP6587908B2 (en) | 2015-11-10 | 2015-11-10 | Proton pump function promoter |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017088537A JP2017088537A (en) | 2017-05-25 |
| JP6587908B2 true JP6587908B2 (en) | 2019-10-09 |
Family
ID=58769644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015220123A Active JP6587908B2 (en) | 2015-11-10 | 2015-11-10 | Proton pump function promoter |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6587908B2 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3156224B2 (en) * | 1991-02-23 | 2001-04-16 | 有限会社野々川商事 | Anti-inflammatory agent |
| JP2001151685A (en) * | 1999-11-25 | 2001-06-05 | Lion Corp | Composition for external use |
| JP2015124188A (en) * | 2013-12-26 | 2015-07-06 | 日本メナード化粧品株式会社 | Sebum synthesis inhibitor |
-
2015
- 2015-11-10 JP JP2015220123A patent/JP6587908B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017088537A (en) | 2017-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7054242B2 (en) | Hair papilla cell activation promoter and VEGF production promoter | |
| JP5283873B2 (en) | Whitening composition | |
| JPH08325156A (en) | Skin preparation for external use, drink and food product containing steviol glycoside | |
| KR20170040002A (en) | Cosmetic Composion for Acne Improvement Containing Butanol Fraction of Red Ginseng Ethanol Extract | |
| JP6753602B2 (en) | Proton pump function accelerator | |
| JP2015124188A (en) | Sebum synthesis inhibitor | |
| KR101964249B1 (en) | Composition for preventing, improving or treating atopic dermatitis comprising mixture of Torilis japonica extract and copper tripeptide-1 as effective component | |
| JP6267957B2 (en) | Sebum synthesis inhibitor | |
| JP6902329B2 (en) | Inhibitor of sebaceous gland cell activation | |
| CN113613666A (en) | Composition for relieving skin irritation and protecting skin caused by environmental pollution factor comprising myristica fragrans extract or macelignan as effective ingredient | |
| KR102158134B1 (en) | Antibacterial composition comprising an extract of schisandra chinesis | |
| JP6320034B2 (en) | Sebum synthesis accelerator | |
| JP6371520B2 (en) | Sebum synthesis accelerator | |
| JP6587908B2 (en) | Proton pump function promoter | |
| JP6908265B2 (en) | Apoptosis inhibitor | |
| JP4421847B2 (en) | Lipolysis accelerator | |
| JP6341661B2 (en) | Sebum synthesis accelerator | |
| JP2017088538A (en) | Filaggrin production promoter | |
| JP6646408B2 (en) | Ceramide production promoter | |
| JP2005194239A (en) | Ceramide synthesis promotor and skin care preparation for external use | |
| JP5313524B2 (en) | Anti-inflammatory agent and anti-inflammatory skin external preparation | |
| JP2009191043A (en) | Elastase inhibitor | |
| KR20170082026A (en) | Composition for prevention of hair loss or promotion of hair growth comprising ginsenoside F5 | |
| KR20180010084A (en) | Composition for moisturing skin comprising trans-3-O-galloyl-3,3',5,5',7- pentahydroxyflavan | |
| JP2023025885A (en) | histidase production promoter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180921 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190709 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190821 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190910 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190911 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6587908 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |